Equities

MicroPort NeuroTech Ltd

MicroPort NeuroTech Ltd

Actions
Health CareMedical Equipment and Services
  • Price (HKD)9.12
  • Today's Change0.300 / 3.40%
  • Shares traded4.91m
  • 1 Year change-20.70%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 09:08 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

MicroPort NeuroTech Ltd is a China-based investment holding company. The company is principally engaged in the research and development, manufacturing and sales of neuro-interventional medical devices. The Company's main products include embolization coils, flow-diverting stents and stent grafts. The Company's products mainly cover three major areas of neurovascular diseases, namely hemorrhagic stroke, cerebral atherosclerotic stenosis and acute ischemic stroke. The Company mainly operates its businesses in the domestic and overseas markets.

  • Revenue in HKD (TTM)--
  • Net income in HKD--
  • Incorporated2020
  • Employees571.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biocytogen Pharmaceuticals Beijng Co Ltd774.95m-413.96m3.55bn1.07k--4.18--4.58-1.04-1.041.952.130.273216.215.74726,974.30-14.59---18.88--70.59---53.42--1.24-21.300.4077--34.28--36.38------
CARsgen Therapeutics Holdings Ltd0.00-808.34m3.95bn516.00--2.03-----1.45-1.450.003.380.00----0.00-29.79---32.14----------9.54--0.0452------16.19------
Beijing Luzhu Biotechnology Co Ltd0.00-269.54m4.05bn133.00--3.67-----1.35-1.350.005.45------0.00----------------6.41--0.0185------65.62------
Jiangsu Recbio Technology Co Ltd0.00-618.26m4.05bn472.00--3.47-----1.29-1.290.002.420.00----0.00-25.47---30.68----------2.33--0.378------20.86------
Shandong Boan Biotechnology Co Ltd668.17m-129.04m4.65bn813.00--3.26--6.97-0.2534-0.25341.312.800.27321.352.53821,862.10-5.28---7.02--66.16---19.31--0.8383-7.470.2491--19.80--64.02------
Ocumension Therapeutics266.31m-410.54m4.70bn444.00--1.48--17.66-0.6327-0.63270.41024.570.0783.612.12599,804.80-12.03-38.78-13.21-41.4758.6062.30-154.16-975.823.72--0.0451--54.99--5.68--319.66--
Sihuan Pharmaceutical Holdings Group Ltd2.01bn-58.39m5.04bn2.87k--1.05--2.51-0.0063-0.00630.21630.51350.15720.81014.72700,268.70-2.18-6.85-3.34-9.1069.6475.81-13.85-36.231.35-2.630.1863---14.70-8.6097.23--0.9325--
Ascentage Pharma Group International239.96m-1.00bn5.17bn583.00--79.09--21.53-3.53-3.530.850.2250.08332.382.22411,588.80-34.73-44.93-52.82-57.0486.2487.68-417.02-976.101.42-15.030.9622--5.85100.76-4.84--2.82--
Microport NeuroTech Ltd-100.00bn-100.00bn5.31bn571.00------------------------------------------------21.61--768.73------
Consun Pharmaceutical Group Ltd2.80bn848.05m5.45bn3.13k6.281.385.831.951.061.063.504.830.49812.0810.05895,367.9015.1312.0422.5719.2574.1974.5530.3724.892.62--0.115540.8410.717.0314.8811.01-22.9318.43
ImmuneOnco Biopharmaceuticls Shanghi Inc-100.00bn-100.00bn5.49bn145.00-------------------------------------------------28.25--5.82------
Qyuns Therapeutics Co Ltd0.00-548.86m6.01bn331.00--18.85-----2.47-2.470.001.43------0.00----------------1.64-69.520.5349-------70.28------
Shanghai Fudan-Zhangjiang Bio-Pharm. Co874.75m110.46m6.20bn948.0019.190.8371--7.090.10730.10730.83072.460.28521.441.62922,731.803.597.034.359.0591.4092.1712.5917.263.94568.370.006239.16-17.502.78-21.28-0.632620.490.00
New Horizon Health Ltd1.47bn119.58m6.47bn1.04k59.102.0041.574.400.23930.23933.227.050.45362.162.081,676,824.003.67--3.99--88.74--8.10--10.50--0.1305--259.54--97.40------
Tong Ren Tang Technologies Co Ltd7.32bn637.97m6.83bn4.10k10.700.91674.980.93240.49810.49815.725.810.52120.98355.681,785,383.007.647.6812.1012.3242.0443.5014.6516.112.37--0.144339.9413.046.011.25-2.73-22.260.0178
China Shineway Pharmaceutical Group Ltd4.88bn1.05bn6.91bn3.44k6.030.90925.631.421.391.396.469.200.50731.446.311,420,898.0010.898.0314.159.7775.1574.5521.4717.872.98--0.041136.2914.3211.9434.1413.890.639612.88
Data as of May 31 2024. Currency figures normalised to MicroPort NeuroTech Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

1.10%Per cent of shares held by top holders
HolderShares% Held
China Universal Asset Management Co., Ltd.as of 31 Dec 20232.00m0.34%
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 20231.30m0.22%
China Asset Management Co., Ltd.as of 31 Dec 20231.06m0.18%
Fidelity Management & Research (Hong Kong) Ltd.as of 30 Apr 2024758.84k0.13%
E Fund Asset Management Co. Ltd.as of 31 Dec 2023390.00k0.07%
Penghua Fund Management Co., Ltd.as of 31 Dec 2023247.00k0.04%
China Asset Management (Hong Kong) Ltd.as of 30 Apr 2024197.42k0.03%
Fidelity Management & Research Co. LLCas of 31 Mar 2024154.00k0.03%
TIAA-CREF Investment Management LLCas of 31 Mar 2024146.00k0.03%
Fullgoal Fund Management Co., Ltd.as of 31 Dec 2023138.00k0.02%
More ▼
Data from 31 Dec 2023 - 22 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.